Sinopharm's mRNA COVID vaccine approved for clinical trials

Chinese drugmaker Sinopharm said that its mRNA COVID-19 vaccine against the Omicron variant has received government approval on Thursday to begin clinical trials.

The company has built a 2 billion dose annual capacity production line in Shanghai and will continue to study the vaccine's efficacy.

Search Trends